secwatch / observer
8-K filed May 5, 2026, 7:59 PM ET ticker TEM CIK 0001717115
earnings confidence high sentiment positive materiality 0.80

Tempus AI Q1 revenue $348M (+36% YoY); raises FY2026 guidance to $1.59-1.60B

Tempus AI, Inc.

2026-Q1 EPS reported -$0.71 vs consensus -$0.19 ▼ miss (-266.9%)
item 2.02item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-206317
form_type
8-K
ticker
TEM
cik
0001717115
company_name
Tempus AI, Inc.
filed_at
2026-05-05T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.797900+00:00
generated_at
2026-05-14T23:27:08.899979+00:00
sec_items
["2.02", "7.01", "9.01"]
event_type
earnings
sentiment
positive
materiality_score
0.8
calibrated_materiality_score
0.8
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-206317
json_url
https://secwatch.observer/filing/0001193125-26-206317.json
markdown_url
https://secwatch.observer/filing/0001193125-26-206317.md
text_url
https://secwatch.observer/filing/0001193125-26-206317.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1717115/000119312526206317/0001193125-26-206317-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1717115/000119312526206317/tem-20260505.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

ebe259564bc2e023f7b03124f793a307272ce5c4

Tempus AI, Inc. reported the quarter ended March 31, 2026 results: revenue $348.1 million, net income ($125.9 million), EPS ($0.70). Guidance raised.

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

GME

GameStop Q1 record net income $389.6M, revenue up 14%, new $2B buyback

GameStop Corp. June 2, 2026, 4:43 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

Net sales were $835.3 million for the first quarter

Filing page SEC filing

GTLB

GitLab Q1 revenue $264M (+23% YoY); plans 14% workforce cut, $30-35M charges

Gitlab Inc. June 2, 2026, 4:17 PM ET earnings Items 2.02, 2.05, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

in such filing. --- EX-99.1 (EX-99.1) --- GitLab Reports First Quarter Fiscal Year 2027 Financial Results First Quarter Fiscal Year 2027 Highlights: • Total revenue of $264.2 million, up 23% year-over-year • GAAP operating margin of (6)%; non-GAAP operating margin of 14% • Operating cash flow of $149.2 million and non-GAAP adjusted free cash flow of $146.7

Filing page SEC filing

VSCO

Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook

Victoria's Secret & Co. June 2, 2026, 7:01 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

The Company reported net sales of $1.560 billion for the first quarter of 2026, an increase of 15% compared to net sales of $1.353 billion for the first quarter of 2025 and above the previously communicated guidance range of $1.490 billion to $1.525 billion. Total comparable sales for the first quarter of 2026 increased 13%. The Company reported operating income for the first quarter of 2026 of $76 million compared to operating income of $20 million in the first quarter of 2025. Net income was $48 million, or $0.56 per diluted share, for the first quarter of 2026 compared to net loss of $2 million, or $0.02 per diluted share, for the first quarter of 2025.

Filing page SEC filing

DG

Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance

DOLLAR GENERAL CORP June 2, 2026, 6:54 AM ET earnings Items 2.02, 5.07, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026 Highlights · Net Sales Increased 3.4% to $10.8 Billion · Same-Store Sales Increased 2.0% · Operating Profit Increased 10.8% to $638.5 Million · Diluted Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash Flow From

Filing page SEC filing

HPE

HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework

Hewlett Packard Enterprise Co June 1, 2026, 4:09 PM ET earnings Items 1.01, 2.02, 5.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,

Filing page SEC filing

ACH

Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

ACCENDRA HEALTH INC/VA/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

Commission this morning. ​ Details on First Quarter 2026 Results ​ ​ First Quarter Results (1) ​ ($ in millions, except per share data) ​ ​ ​ 1Q26 ​ ​ ​ 1Q25 Net Revenue ​ $ 627.8 ​ $ 673.9 ​ ​ ​ ​ ​ ​ ​ Loss from continuing operations, net of tax, GAAP ​ $ (6.5) ​ $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP ​ $ (3.1) ​ $ 23.2 ​ ​ ​

Filing page SEC filing

FSK

FSK posts Q1 GAAP loss of $1.57/sh, NAV falls to $18.83; announces $150M preferred, tender, buyback

FS KKR Capital Corp May 11, 2026, 7:59 PM ET earnings Items 1.01, 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

Earnings (Loss) per share of ($1.57), compared to Earnings (Loss) per share of ($0.41) for the quarter ended December 31, 2025

Filing page SEC filing

APC

ARKO Petroleum Q1 net income $8.1M ($4.5M), Adj. EBITDA $36.4M ($30.9M); completes IPO

ARKO Petroleum Corp. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: earnings similar materiality

This filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

Comparable filing

announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Key Highlights (vs. Year-Ago Period) 1,2 • Net income for the quarter increased to $8.1 million compared to $4.5 million. • Adjusted EBITDA for the quarter increased to $36.4 million compared to $30.9 million. • Net cash provided by operating activities for the quarter was

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-206317
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.